OB体育, OB体育官网,OB体育官方网站入口,OB体育比分,OB体育体育资讯

Ruijun Ju, male, born in 1986. He obtained his Bachelor's degree in Pharmacy (Science) from the School of Pharmaceutical Sciences, Peking University in 2010, and his Master's and Ph.D. degrees in Pharmaceutics from Peking University in 2012 and 2015 respectively. Since September 2015, he has been working as a Professor at the School of Chemical Engineering, Beijing Institute of Petrochemical Technology, teaching courses such as Pharmaceutics and Molecular Biology.

His current research focuses on novel anti-tumor drug delivery systems, extraction and purification of natural products, bioactivity analysis, and cosmetic formulation engineering. He serves as the main drafter of Beijing's technical specifications for safety production in pharmaceutical manufacturing enterprises and as a reviewer for journals such as Phytomedicine and Journal of Drug Delivery Science and Technology.

I. Main Research Areas

• Novel anti-tumor drug delivery systems
• Extraction and purification of natural products
• Bioactivity analysis
• Cosmetic formulation engineering

II. Main Research Projects

1. National Natural Science Foundation for Young Scholars (81703453): Construction of tumor microenvironment-responsive lipid complexes and their effects and mechanisms against breast cancer metastasis, 2018/01-2020/12 (Principal Investigator)
2. Beijing Municipal Education Commission General Science and Technology Project (KM201810017002): Study on the combination of traditional Chinese medicine "Fuzheng Guben" formula and targeted liposomes against drug-resistant lung cancer, 2018.01-2020.06 (Principal Investigator)
3. Beijing Excellent Talent Training Funding Project (2016000020124G058): Construction and characterization of cascade-targeted nanomicelles against tumor stem cells, 2017/01-2018/12 (Principal Investigator)
4. Daxing District Science and Technology Committee Project (KT201801321): Construction of novel anti-free radical ceramide lipid complexes and biological evaluation technology testing, 2018/01-2019/12 (Principal Investigator)
5. Enterprise Commissioned Project: Development of topical preparations - technical development for preparing bioactive ingredients into ointments and aqueous solutions, 2018/07-2018/12 (Principal Investigator)
6. Enterprise Commissioned Project: Survey on the usage of hazardous chemicals in pharmaceutical manufacturing enterprises in Daxing District, 2018/07-2018/09 (Principal Investigator)
7. Enterprise Commissioned Project: Research and technical development for preparing facial mask liquid into solid form samples, 2018/01-2019/01 (Principal Investigator)
8. Enterprise Commissioned Project: Screening of active fractions from toad venom extracts, 2016/08-2016/11 (Principal Investigator)

III. Representative Academic Papers

1. Ju RJ#, Mu LM#, Lu WL*, et al. (2018). Development of functional docetaxel nanomicelles for treatment of brain glioma. Artificial Cells, Nanomedicine and Biotechnology. doi: 10.1080/21691401.2018.1446971. [Epub ahead of print]
2. Ju RJ, Li XT*, et al. (2018). Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer. Artificial Cells, Nanomedicine and Biotechnology. doi: 10.1080/21691401.2018.1433187. [Epub ahead of print]
3. Ju RJ, Li XT*, et al. (2018). Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels. Journal of Drug Targeting. doi: 10.1080/1061186X.2018.1428809. [Epub ahead of print]
4. Gu QY, Ju RJ*, Li XT*, et al. (2018). Nanostructured Layered Terbium Hydroxide Containing NASIDs: In Vitro Physicochemical and Biological Evaluations. Journal of Nanoscience and Nanotechnology, 18, 5320-5326.
5. Zeng F#, Ju RJ#, Lu WL*, et al. (2018). Efficacy in Treating Lung Metastasis of Invasive Breast Cancer with Functional Vincristine Plus Dasatinib Liposomes. Pharmacology, 101(1-2), 43-53.
6. Ju RJ, Li XT*, et al. (2017). PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer. Journal of Liposome Research. doi: 10.1080/08982104.2017.1327542. [Epub ahead of print]
7. Ju RJ, Gu QY*. (2017). Biohybrid based on layered terbium hydroxide and applications as drug carrier and biological fluorescence probe. Applied Organometallic Chemistry, e3926.
8. Mu LM#, Ju RJ#, Lu WL, et al. (2017). Dual-functional drug liposomes in treatment of resistant cancers. Advanced Drug Delivery Reviews, 115, 46-56.
9. Ju RJ#, Zeng F#, Lu WL*, et al. (2016). Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma. International Journal of Nanomedicine, 11, 1131-46.
10. Ju RJ, Lu WL*, et al. (2014). Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials, 35(26), 7610-21.
11. Ju RJ, Lu WL*, et al. (2013). Targeting drug delivery systems for circumventing multidrug resistance of cancers. Therapeutic Delivery, 4(6), 667-71.
12. Ju RJ#, Huang RJ#, Lu WL*, et al. (2012). Separation of injectable salidroside by column chromatography of macroporous resins for treating myocardial ischemia. Science China Chemistry, 55(7), 1435-44.
13. Ju RJ, Li XT*, et al. (2017). Determination of main drug content in cell-penetrating peptide modified paclitaxel and tamoxifen liposomes. Chinese Journal of Ethnomedicine and Ethnopharmacy, 26(21), 13-15.
14. Ju RJ, Li XT*, et al. (2017). Preparation of RGD peptide-modified vinorelbine-tetrandrine liposomes and study on their in vitro tumor inhibition effects. China Pharmacy, 28(25), 3549-3552.
15. Ju RJ, Lu WL*, et al. (2017). Determination of main drug content and in vitro release study of functionalized epirubicin liposomes. Journal of Beijing Institute of Petrochemical Technology, 25(02), 6-10.
16. Ju RJ, Zhang Q*, Lu WL*, et al. (2012). Preparation of salidroside injection and its pharmacokinetic study in rats. Chinese Pharmaceutical Journal, 47(18), 1497-1502.